Luigi Sacco Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy.
Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy.
Int J Clin Pract. 2021 Apr;75(4):e13946. doi: 10.1111/ijcp.13946. Epub 2020 Dec 26.
Hypoalbuminemia is frequently observed in patients with SARS-CoV-2 infection although its underlying mechanism and relationship with the clinical outcome still need to be clarified.
We retrospectively evaluated in patients with COVID-19 hospitalised at the Fatebenefratelli-Sacco Hospital in Milan, the prevalence of hypoalbuminemia, its association with the severity of COVID-19, with the levels of C-reactive protein, d-dimer and interleukin-6 and with clinical outcome over a follow-up period of 30 days. Urinalysis was evaluated in a subgroup of patients.
Serum albumin levels <30 g/L were found in 105/207 (50.7%) patients at hospital admission. Overall, the median albumin value was 29.5 g/L (IQR 25-32.8). A negative association was found between albumin levels and severity of COVID-19 (P < .0001) and death (P = .003). An inverse correlation was observed between albumin and both C-reactive protein and D-dimer at hospital admission (r = -.487 and r = -.479, respectively; P < .0001). Finally, a positive correlation was found between albumin levels and eGFR (r = .137; P = .049). Proteinuria was observed in 75% of patients with available data and it did not differ between patients with hypoalbuminemia and those with albumin ≥30 g/L (81% and 67%, respectively; P = .09).
In patients with COVID-19, hypoalbuminemia is common and observed in quite an early stage of pulmonary disease. It is strictly associated with inflammation markers and clinical outcome. The common finding of proteinuria, even in the absence of creatinine increase, indicates protein loss as a possible biomarker of local and systemic inflammation worthwhile to evaluate disease severity in COVID-19.
尽管 SARS-CoV-2 感染患者常出现低白蛋白血症,但这种现象的潜在机制及其与临床结局的关系仍有待阐明。
我们对米兰 Fatebenefratelli-Sacco 医院收治的 COVID-19 患者进行了回顾性评估,调查了低白蛋白血症的发生率,及其与 COVID-19 严重程度、C 反应蛋白、D-二聚体和白细胞介素 6 水平以及 30 天随访期间临床结局的关系。在部分患者中评估了尿分析。
入院时,207 例患者中有 105 例(50.7%)血清白蛋白水平<30 g/L。总体而言,白蛋白中位数为 29.5 g/L(IQR 25-32.8)。白蛋白水平与 COVID-19 严重程度(P<0.0001)和死亡(P=0.003)呈负相关。入院时白蛋白与 C 反应蛋白和 D-二聚体呈负相关(r=-0.487 和 r=-0.479,均 P<0.0001)。最后,白蛋白水平与 eGFR 呈正相关(r=0.137;P=0.049)。有可用数据的患者中,75%的患者出现蛋白尿,低白蛋白血症患者和白蛋白≥30 g/L 患者的蛋白尿发生率无差异(分别为 81%和 67%,P=0.09)。
在 COVID-19 患者中,低白蛋白血症很常见,且在肺部疾病的早期阶段就已出现。它与炎症标志物和临床结局密切相关。蛋白尿的常见发现,即使没有肌酐增加,也表明蛋白质丢失是局部和全身炎症的一个可能生物标志物,值得在 COVID-19 中评估疾病严重程度。